These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 34861013)

  • 21. Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir.
    Peterson GE
    Curr Med Res Opin; 2006 Dec; 22(12):2613-9. PubMed ID: 17166343
    [TBL] [Abstract][Full Text] [Related]  

  • 22. No higher dose requirements with insulin detemir than glargine in type 2 diabetes: a crossover, double-blind, and randomized study using continuous glucose monitoring.
    King AB
    J Diabetes Sci Technol; 2010 Jan; 4(1):151-4. PubMed ID: 20167179
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study.
    Galasso S; Facchinetti A; Bonora BM; Mariano V; Boscari F; Cipponeri E; Maran A; Avogaro A; Fadini GP; Bruttomesso D
    Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1112-1119. PubMed ID: 27618501
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasma glucose and hypoglycaemia following exercise in people with Type 1 diabetes: a comparison of three basal insulins.
    Arutchelvam V; Heise T; Dellweg S; Elbroend B; Minns I; Home PD
    Diabet Med; 2009 Oct; 26(10):1027-32. PubMed ID: 19900235
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Short-term effects of NPH insulin, insulin detemir, and insulin glargine on the GH-IGF1-IGFBP axis in patients with type 1 diabetes.
    Ma Z; Christiansen JS; Laursen T; Lauritzen T; Frystyk J
    Eur J Endocrinol; 2014 Oct; 171(4):471-9. PubMed ID: 25005937
    [TBL] [Abstract][Full Text] [Related]  

  • 26. How do detemir and glargine compare when added to oral agents in insulin-naïve patients with type 2 diabetes mellitus?
    Marks JB
    Nat Clin Pract Endocrinol Metab; 2008 Sep; 4(9):490-1. PubMed ID: 18594486
    [TBL] [Abstract][Full Text] [Related]  

  • 27. All-Cause and Cause-Specific Mortality among Users of Basal Insulins NPH, Detemir, and Glargine.
    Strandberg AY; Hoti FJ; Strandberg TE; Christopher S; Haukka J; Korhonen P
    PLoS One; 2016; 11(3):e0151910. PubMed ID: 27031113
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment persistence after initiating basal insulin in type 2 diabetes patients: A primary care database analysis.
    Pscherer S; Chou E; Dippel FW; Rathmann W; Kostev K
    Prim Care Diabetes; 2015 Oct; 9(5):377-84. PubMed ID: 25701545
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacodynamics of insulin detemir and insulin glargine assessed by an isoglycemic clamp method in healthy cats.
    Gilor C; Ridge TK; Attermeier KJ; Graves TK
    J Vet Intern Med; 2010; 24(4):870-4. PubMed ID: 20561185
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of basal insulin therapy on vascular endothelial function and adipokine profiles in people with Type 2 diabetes.
    Makino H; Tanaka A; Hosoda H; Koezuka R; Tochiya M; Ohata Y; Tamanaha T; Miyamoto Y; Kangawa K; Kishimoto I
    Diabet Med; 2016 Dec; 33(12):1737-1743. PubMed ID: 27150701
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Basal supplementation of insulin lispro protamine suspension versus insulin glargine and detemir for type 2 diabetes: meta-analysis of randomized controlled trials.
    Esposito K; Chiodini P; Capuano A; Petrizzo M; Improta MR; Giugliano D
    Diabetes Care; 2012 Dec; 35(12):2698-705. PubMed ID: 23173139
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of one-year costs of type 2 diabetes treatment with insulin glargine or insulin detemir in a basal supported oral therapy (BOT) in Germany.
    Pscherer S; Dietrich ES; Dippel FW; Neilson AR
    Int J Clin Pharmacol Ther; 2010 Feb; 48(2):129-37. PubMed ID: 20137765
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of the incidence and risk of hypoglycemic coma associated with selection of basal insulin in the treatment of diabetes: a Finnish register linkage study.
    Haukka J; Hoti F; Erästö P; Saukkonen T; Mäkimattila S; Korhonen P
    Pharmacoepidemiol Drug Saf; 2013 Dec; 22(12):1326-35. PubMed ID: 24150837
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness and safety of insulin glargine
    Silva TBC; Almeida PHRF; Araújo VE; Acurcio FA; Guerra Júnior AA; Godman B; Alvares J
    Ther Adv Endocrinol Metab; 2018; 9(8):241-254. PubMed ID: 30181850
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus.
    Horvath K; Jeitler K; Berghold A; Ebrahim SH; Gratzer TW; Plank J; Kaiser T; Pieber TR; Siebenhofer A
    Cochrane Database Syst Rev; 2007 Apr; (2):CD005613. PubMed ID: 17443605
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Insulin detemir: a review of its use in the management of diabetes mellitus.
    Keating GM
    Drugs; 2012 Dec; 72(17):2255-87. PubMed ID: 23110609
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The comparison of 24-hour urinary sodium, albumin, and protein excretion in chronic kidney disease patients with type 2 diabetes mellitus using insulin detemir or insulin glargine.
    Afsar B
    Clin Drug Investig; 2013 Oct; 33(10):773-8. PubMed ID: 23943142
    [TBL] [Abstract][Full Text] [Related]  

  • 38. All-Cause and Cardiovascular Mortality Among Insulin-Naïve People With Type 2 Diabetes Treated With Insulin Detemir or Glargine: A Cohort Study in the UK.
    Husemoen LLN; Mørch LS; Christensen PK; Hartvig NV; Feher MD
    Diabetes Ther; 2021 May; 12(5):1299-1311. PubMed ID: 33721211
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glargine and detemir: Safety and efficacy profiles of the long-acting basal insulin analogs.
    Poon K; King AB
    Drug Healthc Patient Saf; 2010; 2():213-23. PubMed ID: 21701633
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-acting Insulin Analogs Effect on gh/igf Axis of Children with Type 1 Diabetes: a Randomized, Open-label, Two-period, Cross-over Trial.
    Cherubini V; Pintaudi B; Iannilli A; Pambianchi M; Ferrito L; Nicolucci A
    Exp Clin Endocrinol Diabetes; 2016 May; 124(5):276-82. PubMed ID: 27023008
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.